0 670

Cited 8 times in

Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea

DC Field Value Language
dc.contributor.author방승민-
dc.contributor.author송시영-
dc.date.accessioned2018-07-20T08:09:10Z-
dc.date.available2018-07-20T08:09:10Z-
dc.date.issued2017-
dc.identifier.issn0344-5704-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/160894-
dc.description.abstractPURPOSE: Everolimus is a standard treatment option for advanced pancreatic neuroendocrine tumors (pNETs). This multicenter study evaluated the efficacy and safety of everolimus in low and intermediate grade advanced pNETs. METHODS: Tumors were graded according to the World Health Organization 2010 classification system. Patients with low or intermediate grade pNETs who received everolimus as first- or second-line chemotherapy between 2002 and 2014 were included. RESULTS: A total of 40 patients with metastatic or recurrent pNETs were included in this study. The median age was 54.5 years (range 19-83 years). Twelve patients (30%) experienced recurrence. There were 11 patients (27.5%) with low grade pNETs and 29 (72.5%) with intermediate. Everolimus was administered as first-line therapy in 30 patients (75%) and as second-line therapy in 10 patients (25%). The median progression-free survival (PFS) of patients with low and intermediate grade pNETs was significantly different (median not reached vs. 11 months, P = 0.015). On multivariate analysis, tumor grade (intermediate grade; HR 6.52, 95% CI 1.31-32.27, P = 0.022) was the only independent prognostic factor for PFS in pNETs. The most common adverse events were stomatitis, skin rash, and anemia. CONCLUSIONS: World Health Organization 2010 grade is the most important determinant for PFS in patients undergoing everolimus treatment for pNETs with an acceptable incidence of adverse events.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherSpringer Verlag-
dc.relation.isPartOfCANCER CHEMOTHERAPY AND PHARMACOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHAnemia/chemically induced-
dc.subject.MESHAnemia/epidemiology-
dc.subject.MESHAntineoplastic Agents/adverse effects-
dc.subject.MESHAntineoplastic Agents/therapeutic use*-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHEverolimus/adverse effects-
dc.subject.MESHEverolimus/therapeutic use*-
dc.subject.MESHExanthema/chemically induced-
dc.subject.MESHExanthema/epidemiology-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Grading-
dc.subject.MESHNeoplasm Recurrence, Local-
dc.subject.MESHPancreatic Neoplasms/drug therapy*-
dc.subject.MESHPancreatic Neoplasms/pathology-
dc.subject.MESHPrognosis-
dc.subject.MESHRepublic of Korea-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHStomatitis/chemically induced-
dc.subject.MESHStomatitis/epidemiology-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHYoung Adult-
dc.titleClinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: a multicenter study in Korea-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorKyong Joo Lee-
dc.contributor.googleauthorJae Hee Cho-
dc.contributor.googleauthorSang Hyub Lee-
dc.contributor.googleauthorSi Young Song-
dc.contributor.googleauthorKwang Hyuk Lee-
dc.contributor.googleauthorSeok Jeong-
dc.contributor.googleauthorJi Kon Ryu-
dc.contributor.googleauthorSang Myung Woo-
dc.contributor.googleauthorSeungmin Bang-
dc.contributor.googleauthorJong Kyun Lee-
dc.contributor.googleauthorTae Hoon Lee-
dc.contributor.googleauthorWoo Hyun Paik-
dc.contributor.googleauthorYong Tae Kim-
dc.contributor.googleauthorWoo Jin Lee-
dc.identifier.doi10.1007/s00280-017-3421-7-
dc.contributor.localIdA01786-
dc.contributor.localIdA02035-
dc.relation.journalcodeJ00437-
dc.identifier.eissn1432-0843-
dc.identifier.pmid28884280-
dc.identifier.urlhttps://link.springer.com/article/10.1007%2Fs00280-017-3421-7-
dc.subject.keywordEverolimus-
dc.subject.keywordPancreatic neuroendocrine tumor-
dc.subject.keywordPrognosis-
dc.subject.keywordTumor grade-
dc.subject.keywordWorld Health Organization classification-
dc.contributor.alternativeNameBang, Seung Min-
dc.contributor.alternativeNameSong, Si Young-
dc.contributor.affiliatedAuthorBang, Seung Min-
dc.contributor.affiliatedAuthorSong, Si Young-
dc.citation.volume80-
dc.citation.number4-
dc.citation.startPage799-
dc.citation.endPage805-
dc.identifier.bibliographicCitationCANCER CHEMOTHERAPY AND PHARMACOLOGY, Vol.80(4) : 799-805, 2017-
dc.identifier.rimsid60773-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.